Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label,

Slides:



Advertisements
Similar presentations
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1 Phase 3 Treatment Naïve Source: Afdhal N, et al. N.
Advertisements

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT-1 and HIV Coinfection NIAID ERADICATE Trial Phase 2a Treatment Naïve and Treatment.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIAID SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Gastroenterology Volume 142, Issue 4, April 2012, Pages 790–795 Tom W. Chu.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.
UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.
ARV-trial.com C-SWIFT Study: grazoprevir/elbasvir + SOF in genotypes 1 or 3, with or without cirrhosis Randomisation 1 : 1 Open-label Design W4 W6 W8.
> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.
SOF/VEL 400/100 mg qd N = 250 W24 SOF + RBV W12 * Randomisation was stratified on prior treatment (naïve or experienced) and cirrhosis (yes or no) ** Metavir.
LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.
C-EDGE TN Study: grazoprevir/elbasvir in genotype 1, 4 or 6 Zeuzem S. Ann Intern Med 2015; 163:1-13 GZR/EBR 100/50 mg qd N = 316 N = 105  Design W12W24.
LDV/SOF Open-label Chronic HCV infection Genotype 1 Failure to achieve SVR 12 on a short-course of 1 st line LDV/SOF-containing regimen No cirrhosis N.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in HCV Genotype 4 NIAID SYNERGY (Genotype 4) Phase 2 Treatment Naïve and Treatment Experienced.
Date of download: 5/28/2016 From: Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B: A Meta-Analysis.
Date of download: 5/28/2016 From: High-Dose Acyclovir Compared with Short-Course Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Liver.
Date of download: 6/1/2016 From: Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus Ann Intern Med. 2015;162(6): doi: /M
Date of download: 6/1/2016 From: Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons Ann Intern Med. 2016;164(2): doi: /M
Hepatitis web study Hepatitis web study Elbasvir-Grazoprevir in Treatment-Naïve HCV Genotype 1, 4 or 6 C-EDGE Treatment Naïve (TN) Phase 3 Treatment Naïve.
Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4):
Date of download: 6/2/2016 From: Antibiotic Self-stewardship: Trainee-Led Structured Antibiotic Time-outs to Improve Antimicrobial Use Ann Intern Med.
Date of download: 6/2/2016 From: Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis.
Date of download: 6/2/2016 From: Internet-Based Self-management Plus Education Compared With Usual Care in Asthma: A Randomized Trial Ann Intern Med. 2009;151(2):
Date of download: 6/3/2016 From: Surgery Versus Nonsurgical Treatment of Lumbar Spinal Stenosis: A Randomized Trial Ann Intern Med. 2015;162(7):
Date of download: 6/9/2016 From: Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus– Infected Patients Without.
Date of download: 6/21/2016 From: Psychological and Behavioral Interventions for Managing Insomnia Disorder: An Evidence Report for a Clinical Practice.
Date of download: 6/23/2016 From: The Anticipated Clinical and Economic Effects of 90–90–90 in South Africa Ann Intern Med. Published online May 31, 2016.
Date of download: 6/23/2016 From: Meta-Analysis: Acupuncture for Low Back Pain Ann Intern Med. 2005;142(8): doi: /
Date of download: 6/24/2016 From: Effectiveness of Manual Physical Therapy and Exercise in Osteoarthritis of the Knee: A Randomized, Controlled Trial Ann.
Date of download: 6/25/2016 From: Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic.
Date of download: 6/25/2016 From: Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis Ann Intern Med. 2015;163(3):
Date of download: 7/5/2016 From: Sunscreen and Prevention of Skin Aging: A Randomized Trial Ann Intern Med. 2013;158(11): doi: /
Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Antiretroviral Therapy on Viral Load, CD4.
Date of download: 7/8/2016 From: Did Medicare Part D Affect National Trends in Health Outcomes or Hospitalizations?: A Time-Series Analysis Ann Intern.
Date of download: 9/16/2016 From: Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report.
Date of download: 9/17/2016 From: Behavioral Therapy to Enable Women with Urge Incontinence to Discontinue Drug Treatment: A Randomized Trial Ann Intern.
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
Date of download: 9/17/2016 From: Topical Treatment of Pressure Ulcers with Nerve Growth Factor: A Randomized Clinical Trial Ann Intern Med. 2003;139(8):
Hepatitis C Molecular Diagnosis in the Era of DAAs July 22, 2016, Tehran Ali Namvar Ph.D of Molecular Genetics Iranian Comprehensive Hemophilia Care Center.
Date of download: 9/19/2016 From: The Implications of Regional Variations in Medicare Spending. Part 2: Health Outcomes and Satisfaction with Care Ann.
Date of download: 9/19/2016 From: Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C Ann Intern Med. 2000;132(4): doi: /
W12 N = 126 C-EDGE HEAD-TO-HEAD Study: GZR/EBR vs SOF + PEF-IFN + RBV in genotype 1 or 4 infection Randomisation * 1:1  Design  Treatment regimens –Co-formulated.
From: Screening for Syphilis Infection in Pregnancy: U. S
From: Two Ways of Knowing: Big Data and Evidence-Based Medicine
Ann Intern Med. 2016;165(7): doi: /M Figure Legend:
From: Benefits and Harms of Statin Therapy for Persons With Chronic Kidney DiseaseA Systematic Review and Meta-analysis Ann Intern Med. 2012;157(4):
Diagnostics in hepatitis C: The end of response-guided therapy?
From: Effects of Low-Carbohydrate and Low-Fat DietsA Randomized Trial
Ann Intern Med. 2016;164(8): doi: /M Figure Legend:
Ann Intern Med. 2017;167(1):1-7. doi: /M Figure Legend:
No HBV or HIV co-infection
From: Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients With Major Depressive Disorder: A Clinical Practice Guideline From the American.
Ann Intern Med. 2014;160(11): doi: /M Figure Legend:
Ann Intern Med. 1999;130(6): doi: / Figure Legend:
From: Systematic Review: Strategies for Using Exercise Therapy To Improve Outcomes in Chronic Low Back Pain Ann Intern Med. 2005;142(9): doi: /
From: Self-Measured Blood Pressure Monitoring in the Management of HypertensionA Systematic Review and Meta-analysis Ann Intern Med. 2013;159(3):
From: Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment ProgramA Randomized Trial Ann Intern Med.
Phase 2 Treatment Naïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIAID SYNERGY: Genotype.
Figure 1 Patients cured of HCV infection
Diagnostics in hepatitis C: The end of response-guided therapy?
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Phase 2 Treatment Naïve and Treatment Experienced
Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3
Yasuhiko Sugawara, Masatoshi Makuuchi 
Volume 155, Issue 5, Pages e2 (November 2018)
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Volume 142, Issue 6, Pages (May 2012)
Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?  Masaru Enomoto, Yoshiki Murakami,
Presentation transcript:

Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial Ann Intern Med. 2015;163(12): doi: /M Proportion of patients with viral load below the LLOQ, by treatment week. One patient in the 4-drug group who was lost to follow-up was counted as 1 of the 2 patients who did not achieve viral load below the LLOQ at week 4 (end of treatment). HCV = hepatitis C virus; LLOQ = lower limit of quantification. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial Ann Intern Med. 2015;163(12): doi: /M HCV viral load, by baseline HCV RNA level and RAV subgroup, in patients treated with ledipasvir and sofosbuvir plus GS Vertical dashed lines indicate end of treatment. HCV = hepatitis C virus; LLOQ = lower limit of quantification; RAV = resistance-associated variant; SVR12 = HCV RNA level below LLOQ at posttreatment week 12. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial Ann Intern Med. 2015;163(12): doi: /M HCV viral load, by baseline HCV RNA level and RAV subgroup, in patients treated with ledipasvir and sofosbuvir plus GS-9451 with or without GS Vertical dashed lines indicate end of treatment. HCV = hepatitis C virus; LLOQ = lower limit of quantification; RAV = resistance-associated variant; SVR12 = HCV RNA level below LLOQ at posttreatment week 12. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial Ann Intern Med. 2015;163(12): doi: /M HCV viral load in patients with genotype 1b infection with low viral load and no RAV with >20-fold resistance at baseline. Vertical dashed line indicates end of treatment. Low viral load is <6 × 106 IU/mL. HCV = hepatitis C virus; LLOQ = lower limit of quantification; RAV = resistance-associated variant. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial Ann Intern Med. 2015;163(12): doi: /M Sustained virologic response, by host or viral characteristic. HCV = hepatitis C virus; RAV = resistance-associated variant; SVR12 = HCV RNA level below lower limit of quantification at posttreatment week 12; VL = viral load. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.